Q

Q32 Bio Inc. (QTTB)

NCM – Real vaqt narxi. Valyuta: USD

5.81

+0.63 (12.16%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Q

Q32 Bio Inc. (QTTB)

NCM – Real vaqt narxi. Valyuta: USD

5.81

+0.63 (12.16%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade

The consensus price target hints at a 163.4% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

05.05.2026

Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 -- -- First patient dosed in SIGNAL-AA Part B open-label extension (OLE) -- -- Completed $10.5 million registered direct offering (RDO) -- -- Cash and cash equivalents of $50.8 million as of March 31, 2026, combined with guaranteed near-term milestone payments from ADX-097 asset sale and proceeds from sales under at-the-market (ATM) program received after the end of the quarter, are expected to provide financial runway into 1H'2028 -- WALTHAM, Mass., May 5, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended March 31, 2026, and provided recent corporate updates.

08.04.2026

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m.

30.03.2026

Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?

The consensus price target hints at a 97.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

30.03.2026

Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive

Q32 Bio is now largely a single-asset story centered on Bempikibart in alopecia areata, with mid-2026 topline data as the key catalyst. Management sold ADX-097 to Akebia, which brings milestone and royalty payments as an extra while concentrating its efforts on Bempikibart's R&D. Bempikibart's prior data and ongoing OLE data suggest durable responses and possible remission. This keeps my long-term alopecia areata thesis alive for QTTB.

27.03.2026

Best Momentum Stocks to Buy for March 27th

MGY, ESCA, and QTTB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 27, 2026.

27.03.2026

New Strong Buy Stocks for March 27th

DNN, CM, MGY, QTTB and FLXS have been added to the Zacks Rank #1 (Strong Buy) List on March 27, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

05.05.2026

Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 -- -- First patient dosed in SIGNAL-AA Part B open-label extension (OLE) -- -- Completed $10.5 million registered direct offering (RDO) -- -- Cash and cash equivalents of $50.8 million as of March 31, 2026, combined with guaranteed near-term milestone payments from ADX-097 asset sale and proceeds from sales under at-the-market (ATM) program received after the end of the quarter, are expected to provide financial runway into 1H'2028 -- WALTHAM, Mass., May 5, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended March 31, 2026, and provided recent corporate updates.

08.04.2026

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m.

10.03.2026

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Completed $10.5 million registered direct offering (RDO) -- -- Completed asset sale of Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics to further enable Company's strategic focus on advancing bempikibart for alopecia areata (AA) -- -- Cash and cash equivalents of $48.3 million as of December 31, 2025, combined with gross proceeds from RDO and guaranteed near-term milestone payments from ADX-097 asset sale, expected to provide financial runway into Q4'27 -- WALTHAM, Mass., March 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended December 31, 2025, and provided recent corporate updates.

18.02.2026

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m.

Search stocks

Q32 Bio Inc. (QTTB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Q32 Bio Inc. (QTTB)

Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade

Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?

Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive

Best Momentum Stocks to Buy for March 27th

New Strong Buy Stocks for March 27th

Videolar

No Data

Press-relizlar

Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference